EICHORCondition: Kidney Neoplasms · Sponsor: Pfizer
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The study is designed to demonstrate that axitinib (AG-013736) is superior to sorafenib in delaying tumor progression in patients with metastatic renal cell cancer after failure of one first line regimen.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Histologically or cytologically confirmed renal cell cancer with a component of clear cell subtype, with metastasis * Evidence of measurable disease * Must have failed one prior systemic first-line regimen for metastatic renal cell cancer Exclusion Criteria: * Prior treatment for metastatic renal cell cancer with more that one systemic first line therapy * Major surgery less than 4 weeks or radiation less than 2 weeks of starting study drug
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| East Valley Hematology and Oncology Medical Group | Burbank, California, United States | — |
| Maurice Berkowtiz, MD | Burbank, California, United States | — |
| Agajanian Institute of Oncology and Hematology | Downey, California, United States | — |
| Los Angeles Hematology/Oncology Medical Group | Glendale, California, United States | — |
| Los Angeles Hematology/Oncology Medical Group | Los Angeles, California, United States | — |
| LAC-USC Medical Center | Los Angeles, California, United States | — |
| USC Norris Cancer Hospital and Clinics | Los Angeles, California, United States | — |
| Kenmar Research Institute | Los Angeles, California, United States | — |
| Metropolitan Hematology/Oncology Medical Group | Los Angeles, California, United States | — |
| Ronald Regan UCLA Medical Center | Los Angeles, California, United States | — |
| UCLA | Los Angeles, California, United States | — |
| Agajanian Institute of Oncology and Hematology | Montebello, California, United States | — |
+ 282 more locations — full list on the registry record.
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT00678392